What question did this study set out to answer?

Investigate whether combining selective thromboxane A2 synthetase inhibitors with low-dose aspirin prevents platelet aggregation while sparing endothelial prostacyclin production.

April 29, 1983Science

Platelet Thromboxane Synthetase Inhibitors with Low Doses of Aspirin: Possible Resolution of the "Aspirin Dilemma"

View Full Paper

Ask AI

Bookmark

Why the study?

Does the combination of thromboxane synthetase inhibitors with low doses of aspirin prevent arachidonate-induced platelet aggregation in vitro?

Key Points

Investigate whether combining selective thromboxane A2 synthetase inhibitors with low-dose aspirin prevents platelet aggregation while sparing endothelial prostacyclin production.
Assessed arachidonate-induced human platelet aggregation in vitro using selective thromboxane A2 inhibitors alone and in combination with low concentrations of aspirin.
Measured prostacyclin synthesis in cultured human endothelial cells exposed to the tested concentrations of aspirin.
Selective thromboxane A2 inhibition alone did not prevent platelet aggregation due to accumulation of proaggregatory cyclooxygenase products, but combined therapy with low concentrations of aspirin successfully prevented aggregation.
Low concentrations of aspirin partially reduced proaggregatory cyclooxygenase metabolites without independently altering platelet aggregation or suppressing prostacyclin synthesis in cultured endothelial cells.

Structured PICO

Does the combination of thromboxane synthetase inhibitors with low doses of aspirin prevent arachidonate-induced platelet aggregation in vitro?

Population

Human platelets in vitro and cultured human endothelial cells

Intervention

Combination of thromboxane synthetase inhibitors with low doses of aspirin

Comparator

Thromboxane synthetase inhibitors alone

Outcome

Prevention of arachidonate-induced aggregation of human plateletssurrogate

The combination of thromboxane synthetase inhibitors with low-dose aspirin may offer greater antithrombotic potential than either drug alone by preventing platelet aggregation while preserving prostacyclin synthesis.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

May support selective antiplatelet regimens sparing prostacyclin; hypothesis-generating and requires in vivo confirmation before clinical consideration.

Cite This Study

Bertelè et al. (1983) studied this question.

synapsesocial.com/papers/6a87dbee02f504243ce9688f https://doi.org/10.1126/science.6682245

View Full Paper

Ask AI

Bookmark

Implication

May support selective antiplatelet regimens sparing prostacyclin; hypothesis-generating and requires in vivo confirmation before clinical consideration.

Platelet Thromboxane Synthetase Inhibitors with Low Doses of Aspirin: Possible Resolution of the "Aspirin Dilemma"

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Platelet Thromboxane Synthetase Inhibitors with Low Doses of Aspirin: Possible Resolution of the "Aspirin Dilemma"

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider